NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Nutex Health Inc. (NASDAQ: NUTX) between August 8, 2024 and August 14, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2025. SO WHAT: If you purchased Nutex securities during the Class ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

公司业绩表现 - 奥驰亚集团on!品牌尼古丁袋2025年第二季度出货量达5210万罐 同比增长265% [1] - 公司口服烟草业务调整后经营公司收入(OCI)同比增长109% 利润率从上年同期的656%扩大至687% [3] - 公司股价过去一个月上涨85% 高于行业39%的涨幅 [7] 市场份额与竞争格局 - on!品牌在美国口服烟草市场份额达87% 尼古丁袋品类占整个口服烟草类别52% [1] - 在尼古丁袋子类别中 on!第二季度份额达167% 上半年份额达173% [1] - 菲利普莫里斯国际公司ZYN品牌2025年第二季度美国出货量增长26% 全球销量增长43% 已进入44个市场 [5] - Turning Point Brands现代口服业务销售额达3010万美元 同比增长近八倍 [6] 品牌建设与营销成效 - 公司通过NASCAR赛事 音乐节和高尔夫锦标赛等 activations活动 上半年触达超过17万成年烟草消费者 [2] - 数字营销活动产生19亿次展示 品牌知名度提升7个百分点 [2] 财务估值与预测 - 公司远期市盈率为122倍 低于行业平均1535倍 [10] - 市场共识预期2025年每股收益539美元 2026年555美元 过去30天内均上调1美分 [11] - 当前季度(2025年9月)每股收益预期142美元 下一季度(2025年12月)预期132美元 [12]

CEO.CA's Inside the Boardroom: Dryden Gold - C$7.8M Raise Powers Drill Blitz After 24 g/t HitsSeptember 02, 2025 11:55 AM EDT | Source: CEO.CA Technologies Ltd.[DATELINE]CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining explorers.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular free financial websites and apps in Canada and for investors globally - wi ...

公司近期表现 - 公司在最初分析约四个月后显示出一些有趣的发展动态 尽管仍难以从合同取消中恢复 但近期出现新的希望迹象 [1] 作者背景与投资经验 - 作者在物流行业拥有近二十年从业经验 在股票投资和宏观经济分析领域有近十年经验 [1] - 当前重点关注东盟及纽交所/纳斯达克的银行 电信 物流和酒店类股票 [1] - 自2014年起参与菲律宾股市交易 重点投资银行 电信和零售板块 [1] - 2020年进入美国市场 通过寻求alpha平台进行投资研究 持有美国银行 酒店 航运和物流公司股票 [1]

In recent days with new all-time highs being reached in the markets, I am becoming ever more cautious regarding any new investments. I am also making some adjustments to my own portfolio, which has become too dependent onNow retired, I am an income-oriented investor seeking high yield income to support my lifestyle in retirement.I became deeply interested in the stock market beginning in late 2007 (bad timing for me but worse for my uncle) when I received an unexpected inheritance. Since that time I have do ...

投资背景与策略 - 投资生涯始于2011年高中时期 主要投资领域包括房地产投资信托基金（REITs）、优先股和高收益债券[1] - 当前投资策略结合长期股票多头头寸、备兑看涨期权和现金担保看跌期权[1] - 投资方法论纯粹基于基本面长期视角 重点关注REITs和金融行业 偶尔涉及ETF及宏观交易理念驱动的个股分析[1] 披露声明 - 分析师未持有任何提及公司的股票、期权或衍生品头寸 且未来72小时内无相关头寸计划[2] - 分析内容基于独立观点 未获得除Seeking Alpha外任何形式的补偿[2] - 与提及股票公司不存在商业关联关系[2] 平台性质说明 - 过往业绩不保证未来结果 不提供特定投资适用性建议[3] - 观点可能不代表Seeking Alpha整体立场 平台非持牌证券交易商、经纪商或投资顾问[3] - 分析师团队包含未受机构认证的专业投资者与个人投资者[3]

Key Takeaways Tesla cut the Model 3 rear-wheel drive price in China by 3.7%, with deliveries starting this month.New versions of Model 3 and Model Y aim to counter slowing demand in China's competitive EV market.Price war pressure has hurt automakers, with BYD posting its first profit decline in over three years.Tesla, Inc. (TSLA) has cut the price of its Model 3 rear-wheel drive in China as competition from domestic automakers intensifies. Deliveries of this version are expected to start this month. The ne ...

ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Capricor’s four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased shares of Capricor between October 9, 2024 and July 10, 2025, and exp ...

Value investors, including yours truly, are a stubborn bunch. The years-long trend of growth over value has stung allocations heavy in sectors like Financials, Industrials, and Energy. Though there have been occasional bouts of blue-chip stocks over storyFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My pa ...